INMB
INmune Bio Inc.
$1.43
+0.00%
2026-05-08
About INmune Bio Inc.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; GOSH; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Key Fundamentals
Forward P/E
-2.73
EPS (TTM)
$-1.86
ROE
-165.2%
Profit Margin
0.0%
Debt/Equity
4.40
Price/Book
1.63
Beta
1.05
Market Cap
$38.4M
Avg Volume (10D)
235K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$1.67
60D Low
$1.09
Avg Volume
396K
Latest Close
$1.43
Get breakout alerts for INMB
Sign up for Breakout Scanner to receive daily notifications when INMB triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
INmune Bio Inc. (INMB) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors INMB daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. INMB operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.